The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid Tumors

Exclusion Criteria

• •Brain metastasis or spinal cord compression that has not yet been definitively treated with surgery and/or radiation, and/or patients with brain metastasis that have been receiving corticosteroids.
• •Previously diagnosed and treated central nervous system (CNS) metastases or spinal cord compression that has not been clinically stable for at least 2 months.
• •Treatment with anti-tumor therapy within 4 weeks before the start of study treatment, with the following exception: Patients with metastatic prostate cancer on maintenance hormonal therapy, provided they meet all other eligibility criteria.
• •Current, serious or uncontrolled, systemic illness.
• •Recent stroke (within the past 6 months).
• •Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory drugs (NSAIDs).
• •History of cardiovascular conditions.
• •Any other disease, gastrointestinal abnormality, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.
• •Receipt of any investigational agent, or participation in any other clinical study, within 4 weeks before the start of study treatment.
• •Major surgery within 4 weeks before the start of study treatment, without complete recovery.
• •Significant traumatic injury within 3 weeks before the start of study treatment (All wounds must be fully healed prior to Day 1).
• •Uncontrolled excess calcium levels.
• •Known human immunodeficiency virus (HIV) infection.
• •Inadequate organ function
• •Pregnancy